HUTCHMED Secures $110 Million Licensing Deal with GSK for Promising Solid Tumour Drug, ETPharma
Shanghai: GSK subsidiary GlaxoSmithKline Intellectual Property (No. 4) Ltd will pay a unit of HUTCHMED (China) $110 million…
Browsing Tag